We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ARQT market cap is 1.15B. The company's latest EPS is USD -2.2397 and P/E is -4.43.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 5.19M | 38.11M | 13.53M | 49.57M | 30.86M |
| Operating Income | -66.76M | -36.9M | -61.17M | -31.62M | -50.08M |
| Net Income | -70.99M | -44.77M | -66.28M | -35.38M | -52.33M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 3.69M | 59.61M |
| Operating Income | -43.13M | -136.65M | -206.53M | -301.63M | -241.1M |
| Net Income | -42M | -135.68M | -206.36M | -311.46M | -262.14M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 320.69M | 292.96M | 341.37M | 478.54M | 444.76M |
| Total Liabilities | 240.18M | 246.24M | 252.7M | 253.6M | 258.33M |
| Total Equity | 80.51M | 46.72M | 88.67M | 224.94M | 186.43M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 107.01M | 298.27M | 408.15M | 449.27M | 341.37M |
| Total Liabilities | 5.55M | 27.65M | 110.48M | 239.69M | 252.7M |
| Total Equity | -65.03M | 270.62M | 297.68M | 209.58M | 88.67M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -146.83M | -190.81M | -247.06M | -31.6M | -76.72M |
| Investing | 196.87M | 242.42M | 180.23M | -28.7M | -90.83M |
| Financing | 1.17M | 2.03M | 101.32M | 161.76M | 163.22M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -42.84M | -113.03M | -174.63M | -257.72M | -247.06M |
| Investing | -26.33M | -181.82M | -75.95M | -87.2M | 180.23M |
| Financing | 93.1M | 298.15M | 281.95M | 301.8M | 101.32M |
| Market Cap | 1.15B |
| Price to Earnings Ratio | -4.43 |
| Price to Sales Ratio | 19.5 |
| Price to Cash Ratio | 13.15 |
| Price to Book Ratio | 13.11 |
| Dividend Yield | - |
| Shares Outstanding | 117.04M |
| Average Volume (1 week) | 2.49M |
| Average Volume (1 Month) | 2.36M |
| 52 Week Change | 362.44% |
| 52 Week High | 13.17 |
| 52 Week Low | 1.76 |
| Spread (Intraday) | 0.02 (0.2%) |
| Company Name | Arcutis Biotherapeutics Inc |
| Address |
3411 silverside road tatnall wilmington, delaware 19810 |
| Website | https://www.arcutis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
